Major Depressive Disorder Clinical Trial
— PARADIGMOfficial title:
A Randomized, Double-Blind, Placebo-Controlled Trial of Solriamfetol in Subjects With Major Depressive Disorder
PARADIGM (Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the safety and efficacy of solriamfetol for the treatment of major depressive disorder (MDD) in adults.
| Status | Recruiting |
| Enrollment | 300 |
| Est. completion date | December 2025 |
| Est. primary completion date | December 2025 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 65 Years |
| Eligibility | Inclusion Criteria: - Currently meets the DSM-5 criteria for MDD without psychotic features, based on the SCID-5-CT - Current major depressive episode - Male or female, aged 18 to 65 inclusive Exclusion Criteria: - Prior exposure to solriamfetol/Sunosi, through either a clinical study or prescription - Unable to comply with study procedures - Medically inappropriate for study participation in the opinion of the investigator |
| Country | Name | City | State |
|---|---|---|---|
| United States | Clinical Research Site | Boston | Massachusetts |
| United States | Clinical Research Site | Brooklyn | New York |
| United States | Clinical Research Site | Chicago | Illinois |
| United States | Clinical Research Site | Cromwell | Connecticut |
| United States | Clinical Research Site | Encino | California |
| United States | Clinical Research Site | Everett | Washington |
| United States | Clinical Research Site | Hialeah | Florida |
| United States | Clinical Research Site | Hickory | North Carolina |
| United States | Clinical Research Site | Jacksonville | Florida |
| United States | Clinical Research Site | Las Vegas | Nevada |
| United States | Clinical Research Site | Lemon Grove | California |
| United States | Clinical Research Site | Media | Pennsylvania |
| United States | Clinical Research Site | Memphis | Tennessee |
| United States | Clinical Research Site | Oceanside | California |
| United States | Clinical Research Site | Oklahoma City | Oklahoma |
| United States | Clinical Research Site | Orlando | Florida |
| United States | Clinical Research Site | Orlando | Florida |
| United States | Clinical Research Site | Orlando | Florida |
| United States | Clinical Research Site | Redlands | California |
| United States | Clinical Research Site | Riverside | California |
| United States | Clinical Research Site | Rochester | New York |
| United States | Clinical Research Site | Saint Charles | Missouri |
| United States | Clinical Research Site | Sherman Oaks | California |
| United States | Clinical Research Site | Upland | California |
| United States | Clinical Research Site | Wichita Falls | Texas |
| Lead Sponsor | Collaborator |
|---|---|
| Axsome Therapeutics, Inc. |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Montgomery-Åsberg Depression Rating Scale (MADRS) | 6 weeks | ||
| Primary | Incidence of treatment-emergent adverse events | 6 weeks |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
| Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
| Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
| Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
| Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
| Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
| Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
| Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
| Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
| Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
| Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
| Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
| Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
| Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
| Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
| Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
| Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
| Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
| Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A | |
| Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 |